



18F

0360
#13

Dkt No. 59597-E/JPW/AJM/DRM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Neil T. Parkin and Rainer A. Ziermann
Serial No. : 09/874,472
Filed : June 4, 2001
For : MEANS AND METHODS FOR MONITORING PROTEASE
INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING
THERAPEUTIC DECISIONS IN THE TREATMENT OF
HIV/AIDS

1185 Avenue of the Americas
New York, New York 10036
October 9, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**Exhibit A**). A copy of the disclosures listed below as items 1-3 are attached as **Exhibits 1-3**.

1. U.S. Patent No. 5,837,464 (Capon et al.) issued November 17, 1998;
2. Young, B. et al., Resistance Mutations In Protease And Reverse Transcriptase Genes Of Human Immunodeficiency Virus Type 1 Isolates From Patients With Combination Antiretroviral Therapy Failure, Journal of Infectious Diseases, Vol. 178, No.5, pages 1497-1501 (November 1998); and
3. Hertogs et al., A Rapid Method For Simultaneous Detection Of Phenotypic Resistance To Inhibitors Of Protease And

Applicants: Neil T. Parkin and Rainer A. Ziermann
Serial No.: 09/874,472
Filed : June 4, 2001
Page 2

Reverse Transcriptase In Recombinant Human Immunodeficiency
Virus Type 1 Isolates from Patients Treated With
Antiretroviral Drugs, Antimicrobial Agents And
Chemotherapy, Vol. 42, No. 2, pages 269-276 (February
1998).


PCT International Application No. PCT/US02/01682, filed January
8, 2002 is a foreign counterpart application of the subject
application. A Search Report was issued on July 9, 2002 in
connection with PCT/US02/01682. A copy of the Search Report is
attached hereto as **Exhibit B**. The above listed references 1-3
were cited in the Search Report.

If a telephone interview would be of assistance in advancing
prosecution of the subject application, applicants' undersigned
attorneys invite the Examiner to telephone them at the number
provided below.

Applicants: Neil T. Parkin and Rainer A. Ziermann
Serial No.: 09/874,472
Filed : June 4, 2001
Page 3


No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231.



Alan J. Morrison
Reg. No. 37,399

10/09/02
Date

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket No. 2793/59597-E/JPW/AJM/DRM		Serial No. 09/874,472	
		Applicants Neil T. Parkin and Rainer A. Ziermann			
		Filing Date June 4, 2001		Group	

U.S. PATENT DOCUMENTS														
Examiner Initial	Document Number								Date	Name	Class	Subclass	Filing Date if Appropriate	
	5	8	3	7	4	6	4	17 Nov 98	Capon et al					
	Document Number								Date	Country	Class	Subclass	Translation	
													Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Young, B. et al., Resistance Mutations In Protease And Reverse Transcriptase Genes Of Human Immunodeficiency Virus Type 1 Isolates From Patients With Combination Antiretroviral Therapy Failure, <u>Journal Of Infectious Diseases</u> , Vol. 178, No. 5, pages 1497-1501 (November 1998).
	Hertogs et al., A Rapid Method For Simultaneous Detection Of Phenotypic Resistance To Inhibitors Of Protease And Reverse Transcriptase In Recombinant Human Immunodeficiency Drugs. <u>Antimicrobial Agents And Chemotherapy</u> , Vol. 42, No. 2, pages 269-276 (February 1998).

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.